🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Follow-up for #early breast cancer is a major concern with several topics still debated. Published in #CancerTreatmentReviews an Italian Association of Multidisciplinary Oncology Groups (#AIGOM) consensus, discussing several topics in this field 🫱🏻‍🫲🏽 ➡️ sciencedirect.com/science/articl…

📌 The role of radiation therapy in the multidisciplinary management of male breast cancer: a systematic review and meta-analysis. OncoAlert #OncoAlertAF 🔗proud to share our research article: sciencedirect.com/science/articl… Agnese Prisco Maria Carmen De Santis Fiorenza De Rose Nadia Pasinetti

The Full Program for #SABCS24 is out SABCS Look who’s around… #radonc #medonc #surgonc #BreastCancer #OncoAlert OncoAlert Università di Firenze Azienda Ospedaliero-Universitaria Careggi sabcs.org/FullProgram

Moving beyond mean heart dose: The importance of cardiac substructures in radiation therapy toxicity. onlinelibrary.wiley.com/doi/full/10.11…

🧵 SBRT in Oligometastatic Breast Cancer: What does the evidence show? A summary of key studies and their impact on survival. Let’s dive in! 👇 1/ What is Oligometastatic Breast Cancer (OMBC)? OMBC is an intermediate state between localized and widespread metastatic disease,

💊Adjuvant endocrine therapy in pre and post menopausal patients with HR(+) breast cancer 👇 OncoAlert Luca Arecco, MD Elisa Agostinetto #cancer #breast #oncology #MedX

Excellent present by ⁦Matteo Lambertini, MD PhD⁩ on risk reduction surgery in BRCA carriers ( under the age of 40 with a diagnosis of #breastcancer ⁦SABCS⁩ improvement in survival ⁦OncoAlert⁩ #sabcs24

ER low = TNBC . Do you treat them as TNBC ? Excellent slides from SABCS #SABCS24 Yakup Ergün LARVOL OncoAlert

🎙EUROPA Trial: ☢️ shows ⬆️ HRQOL and ⬇️⬇️ side effects vs. endocrine therapy in women 70+ with early-stage breast cancer❗️ OncoAlert 🎯 Objective: •☢️✖️ET as single-modality treatments for women aged ≥70 w/ luminal A-like breast cancer 🧪 Methods: •Design: Non-inferiority,

📌 Clinical Controversies: Omission of Axillary Staging in ER Positive Breast Cancer: Implications on Adjuvant Therapies Topic 1: Omission of Axillary Staging in ER+ Disease – What is The Data? by Dr. E Mittendorf Dana-Farber’s Breast Oncology Center #SABCS24 #day3 OncoAlert #OncoAlertAF

END OF YEAR TOP ALL CANCER TRIALS in 2024! JUST in on 1 JAN 2025: Paper 1: #neoadjuvant checkpoint inhibitor Phase 3 trial in melanoma! #NADINA trial shows ipi+nivo significantly improves EFS vs. adjuvant nivo alone (HR 0.32, p<0.0001). #ASCO24 plenary #Melanoma ASCO

Biomarker-Directed Radiotherapy in Breast Cancer: A Narrative Review is out! JAMA Oncology A robust clinical and analytical validation of biomarkers to ensure clinical utility for RT optimization is still needed ☢️ #radonc #OncoAlert OncoAlert ESTRO pubmed.ncbi.nlm.nih.gov/39820307/

👩🏻‍💻 Technology is revolutionizing #RadiationOncology! 🎯 Advanced #imaging modalities and highly #precise delivery techniques make radiotherapy more #effective than ever 📹 Watch the video and be amazed in witnessing #radiotherapy power ⤵️⤵️⤵️ #fightcancer #AIRO #ESTRO #ASTRO

📌 Pre-Operative Single Fraction Stereotactic Partial Breast Irradiation (S-PBI) for Early-Stage Breast Cancer Patients with Gammapod Technology: Pathological Findings and Ki-67 Evaluation redjournal.org/article/S0360-… 👉🏻 a high dose of S-PBI may be correlated with a Major Response,

This paper is a must-read. Almost certainly the best review of NPC you will read this year!! Many thanks to Melvin LK CHUA | FRCR, PhD, FASCO and colleagues for this contribution.

Could Surgery Become Optional in Early Breast Cancer? Groundbreaking Trial Says Maybe! 🚨 OncoAlert 🎯 Objective: Evaluate if ☢️ alone can safely replace breast surgery in selected 👥 with early-stage invasive breast cancer 🏥 Methods: • Nonrandomized phase 2 trial (N=50) •

We’ve just enrolled the last patient in the EUROPA trial! 926 patients recruited over 4 years across 20 centres An infinite thank you to all patients, investigators, and caregivers who made this incredible journey possible ❤️ OncoAlert #OncoAlert #BreastCancer #radonc #medonc

International consensus on laryngeal preservation strategies in laryngeal and hypopharyngeal cancer - kudos to Marco Ferrari, Piero Nicolai and Paolo Bossi for leading this much needed initiative! sciencedirect.com/science/articl…

It was a great pleasure present the long term results of PMRT in ALTTO trial. PMRT teduced locoregional recurrence in patients with positive lymphonodes and improved time to distant recurrence and overall survival in pN2 disease. These results confimed Oxford metanalysis.

In this month's Radiotherapy & Oncology Van Aken, et al describe a framework to assess interactions and safety of targeted therapes or #Immunotherapy combinations with #Radiotherapy ➡️Pragmatic and biologically informed guidance on how to address 🔗doi.org/10.1016/j.rado…